Business · Companies · 16 hrs ago
LTR Pharma secures Indian patent for nasal erectile dysfunction treatments
Australian company LTR Pharma has secured an Indian patent for formulation features used in its nasal erectile dysfunction treatments, SPONTAN and ROXUS.
The patent is set to run until 2041, subject to maintenance requirements and remaining valid.
Vardenafil, the active ingredient, is already a generic drug, so the company’s key distinction is its nasal formulation.
In a study of 27 healthy men, SPONTAN reached peak blood concentration in a median of 10 minutes, compared with 60 minutes for an oral vardenafil tablet.
In Australia, more than 2,000 bottles of SPONTAN had been dispensed by October 20, while the first patient-specific ROXUS prescriptions reached US patients in October; ROXUS is compounded and has not been reviewed or approved by the FDA.
The patent adds protection as LTR expands access and develops SPONTAN, including work towards a planned US regulatory application.
The company is targeting the start of a pivotal SPONTAN Phase III study in the first half of 2027.
LTR Pharma has secured an Indian patent for formulation technology used in its SPONTAN and ROXUS nasal erectile dysfunction treatments.
Indian Patent No. 605429 is titled Formulations and Methods for Treating Erectile Dysfunction.
The patent protection extends to May 2041, subject to maintenance requirements and continued validity.
The company said the patent supports its intellectual property strategy as it advances clinical development and commercial programs.
The grant follows October milestones including final Phase II results, dispensing growth in Australia and the first US ROXUS prescription fulfilments.
- Who
- LTR Pharma, an Australian pharmaceutical company.
- What
- It secured an Indian patent for formulation technology supporting its SPONTAN and ROXUS nasal erectile dysfunction treatments.
- When
- The patent grant was reported on November 9, 2026.
- Where
- India.
- Why
- The patent strengthens protection for the company’s intranasal formulation technology as it advances clinical and commercial programs.
This story does not have two clearly opposing sides.
LTR reported final results from its 27-participant Phase II pharmacokinetic study.
More than 2,000 bottles of SPONTAN had been dispensed in Australia.
The first patient-specific ROXUS prescriptions reached US patients through Shed’s Mavrox telehealth platform and Strive Pharmacy.
Stockhead reported that LTR Pharma had secured the Indian patent.
- Patent number
- 605429
- Patent title
- Formulations and Methods for Treating Erectile Dysfunction
- Protection extends to
- May 2041, subject to maintenance requirements and continued validity
- Phase II study
- 27 participants
- SPONTAN dispensing in Australia
- More than 2,000 bottles by October 20
- Phase III target
- First half of 2027
What people are saying
We are pleased with the scope of the granted claims and the additional protection they provide for our intranasal formulation technology
Protecting our intellectual property remains an important part of our strategy as we advance our clinical and commercial programs.